12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Renaissance Acquisition Holdings LLC, GlaxoSmithKline sales and marketing update

GlaxoSmithKline granted Renaissance rights to market six approved dermatology drugs and three formulations of Zovirax acyclovir in the U.S. The dermatology products are Evoclin clindamycin, a foam formulation of 1% clindamycin to treat infections; Extina 2% ketoconazole topical foam to treat seborrheic dermatitis in immunocompetent patients; topical...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >